Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
amphotericin B + caspofungin + voriconazole
- Development stage
- Preclinical
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A triple antifungal combination therapy that combines three different classes of antifungal agents. This combination brings together amphotericin B (a polyene that forms pores in fungal cell membranes), caspofungin (an echinocandin that inhibits fungal cell wall synthesis), and voriconazole (a triazole that inhibits ergosterol biosynthesis). The triple combination has shown synergistic effects against Aspergillus species at specific concentrations, though interactions are concentration-dependent and can be antagonistic at higher concentrations of amphotericin B and voriconazole.
02
Targets
Beyond the preview
Go deeper on amphotericin B + caspofungin + voriconazole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on amphotericin B + caspofungin + voriconazole.